Navigation Links
Handa Pharmaceuticals Announces Submission of its First-to-File ANDA for AstraZeneca's SEROQUEL(R) XR
Date:7/31/2008

FREMONT, Calif., July 31 /PRNewswire/ -- Handa Pharmaceuticals, LLC ("Handa"), a specialty pharmaceutical company based in Fremont, California, today confirmed that its Abbreviated New Drug Application ("ANDA") for Quetiapine Fumarate Extended-Release Tablets, the generic version of AstraZeneca's SEROQUEL(R) XR, has been accepted for filing by the U.S. Food and Drug Administration ("FDA"). Based upon available information, Handa believes that it is the first applicant to file an ANDA for SEROQUEL(R) XR containing a Paragraph IV certification, under the provisions of the Hatch- Waxman Act. Should its ANDA be approved by the FDA, Handa believes that its product will be entitled to 180 days of generic market exclusivity.

About Handa Pharmaceuticals, LLC

Handa Pharmaceuticals, LLC is a specialty pharmaceutical company that was established in the San Francisco Bay area in November 2005. Handa's executive leadership has a proven track record of developing controlled-release prescription pharmaceutical products that are difficult to formulate. For more information, please visit http://www.handapharma.com.

Forward-Looking Statements

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Handa's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Handa disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Handa's current expectations depending upon a number of factors affecting Handa's business. These factors include, among others, patents and other intellectual property rights held by competitors and other third parties and the uncertainty of the outcome of litigation related to such patents and intellectual property rights; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; the impact of competitive products and pricing; market acceptance of and demand for Handa's products; difficulties or delays in manufacturing; and other risks and uncertainties.

SEROQUEL(R) and SEROQUEL(R) XR are registered trademarks of the AstraZeneca group of companies.

Contact: Stephen Cary of Handa Pharmaceuticals, LLC, +1-510-354-2888


'/>"/>
SOURCE Handa Pharmaceuticals, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
2. Trubion Pharmaceuticals Provides Announcement Dates for Second Quarter and First Six Months Earnings Conference Call
3. DoctorDirectory to Co-market VoSpire ER(R) with DAVA Pharmaceuticals, Inc.
4. Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
5. Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP
6. New Natural Product from Zurich Pharmaceuticals Downs Appetite
7. AUDIO from Medialink and Duramed Pharmaceuticals: Not Your Mothers Menopause
8. Genesis Pharmaceuticals Announces New Board Member and Forms Committees
9. Sound Pharmaceuticals Receives Additional DoD Funding for Its Hearing Regeneration Product
10. AUDIO from Medialink and Duramed Pharmaceuticals: Relief for Women Experiencing Surgical Menopause
11. Genesis Pharmaceuticals Announces SFDA Approval for Radix Isatidis Dispersible Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... While it’s often important to take certain medications during the night, finding ... identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX to ... the need to turn on a light when taking medication during the night, allowing ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... Shelton, CT (PRWEB) , ... October 13, 2017 , ... ... and long-term care services, staged a mock evacuation of the facility as part of ... Department, Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
Breaking Medicine Technology: